Abstract: Compounds, methods of synthesis, and methods of cancer treatment by arylidene-1,3-dioxane-4,6-diones. A Meldrum's acid-based chemistry and hybrid solid-liquid method. The method includes protection of ketone and aldehyde components and simultaneous immobilization on the solid phase, introduction of substituents, grafts and derivatives compatible with the protection, detachment and restoration of active carbonyl reactivity, reaction of ketone library with malonate, reacting of the products with the aldehyde library in liquid phase and separation of the products by preparative HPLC.

Abstract: The invention is directed to a method for treating a cancer patient by administering an agent that depletes intracellular ATP along with a purine analog, such as fludarabine. It is also directed to a method for selecting a patient having cancer cells susceptible to depletion of their intracellular ATP.

Abstract: A method for preparing a single stranded DNA by the polymerase chain reaction in high yield and purity. The method employ one regular primer and one modified primer at the 5?-end. The modified primer has a primer segment linked to an oligo- or polynucleotide segment through a 5?-5?-phosphodiester bond. Using the modified primer, the PCR product includes two complementary DNA strands having different lengths and separable from one another.

Abstract: The invention is directed to a method for treating a cancer patient by administering an agent that depletes intracellular ATP along with a purine analog, such as fludarabine. It is also directed to a method for selecting a patient having cancer cells susceptible to depletion of their intracellular ATP.

Abstract: Compounds, methods of synthesis, and methods of cancer treatment by arylidene-1,3-dioxane-4,6-diones. A Meldrum's acid-based chemistry and hybrid solid-liquid method. The method includes protection of ketone and aldehyde components and simultaneous immobilization on the solid phase, introduction of substituents, grafts and derivatives compatible with the protection, detachment and restoration of active carbonyl reactivity, reaction of ketone library with malonate, reacting of the products with the aldehyde library in liquid phase and separation of the products by preparative HPLC.

Abstract: The present disclosure relates to methods of reducing the number of abnormal PBMC cells in a leukemia patient. The methods may include administering an effective amount of a drug, which may not be indicated for leukemia, or an antibody-drug conjugate. The antibody-drug conjugate includes an antibody selected from the group consisting of an anti-?2-adrenoreceptor antibody, an anti-? adrenoceptor antibody, an anti-trace amine-associated receptor 1 antibody, an anti-dopamine receptor antibody, and an anti-serotonin receptor antibody; a drug selected from the group consisting of isoproterenol, methyldopa, olanzapine, and a derivative thereof; and a linker that conjugates the antibody and the drug.

Abstract: A method of treating leukemia in a patient, the method including obtaining a plasma sample from a patient at a first time point and at a second time point, measuring a gene expression level of a set of core clock genes, and at least one of a first set of peripheral clock genes and a second set of peripheral clock genes, each in the plasma sample at the first time point and in the plasma sample at the second time point. Then determining that a first treatment is effective or ineffective for the patient when a correlation of the gene expression level of the set of core clock genes, the first set of peripheral clock genes, and the second set of peripheral clock genes, and treating the patient accordingly.

Abstract: The present disclosure relates to methods of reducing the number of abnormal PBMC cells in a leukemia patient. The methods may include administering an effective amount of a drug, which may not be indicated for leukemia, or an antibody-drug conjugate. The antibody-drug conjugate includes an antibody selected from the group consisting of an anti-?2-adrenoreceptor antibody, an anti-? adrenoceptor antibody, an anti-trace amine-associated receptor 1 antibody, an anti-dopamine receptor antibody, and an anti-serotonin receptor antibody; a drug selected from the group consisting of isoproterenol, methyldopa, olanzapine, and a derivative thereof; and a linker that conjugates the antibody and the drug.

Abstract: A method of treating leukemia in a patient, the method including obtaining a plasma sample from a patient at a first time point and at a second time point, measuring a gene expression level of a set of core clock genes, and at least one of a first set of peripheral clock genes and a second set of peripheral clock genes, each in the plasma sample at the first time point and in the plasma sample at the second time point. Then determining that a first treatment is effective or ineffective for the patient when a correlation of the gene expression level of the set of core clock genes, the first set of peripheral clock genes, and the second set of peripheral clock genes, and treating the patient accordingly.